About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
Beta Bionics, Inc. (BBNX) Insider Trading
18 open-market trades reported since Jun 25, 2026: 0 purchases worth $0 and 18 sales worth $3.24M.
By insider
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Mark Hopman | Chief Commercial Officer | 0 | $0 | 8 | $2.12M |
| Christy Jones | Director | 0 | $0 | 2 | $169K |
| Mike Mensinger | Chief Product Officer | 0 | $0 | 2 | $142K |
| Sean Saint | CEO | 0 | $0 | 2 | $436K |
| Stephen Feider | CFO | 0 | $0 | 3 | $298K |
| Steven Jon Russell | Chief Medical Officer | 0 | $0 | 1 | $81K |
All trades
| Filed | Insider | Type | Value | 3 mo. after |
|---|---|---|---|---|
| Oct 16 | Mark HopmanChief Commercial Officer | ▼ SELL | $13K | |
| Oct 5 | Mark HopmanChief Commercial Officer | ▼ SELL | $7K | |
| Sep 23 | Christy JonesDirector | ▼ SELL10b5-1 | $148K | |
| Sep 18 | Mark HopmanChief Commercial Officer | ▼ SELL10b5-1 | $665K | |
| Sep 17 | Mark HopmanChief Commercial Officer | ▼ SELL10b5-1 | $620K | |
| Sep 17 | Mike MensingerChief Product Officer | ▼ SELL10b5-1 | $58K | |
| Sep 15 | Mark HopmanChief Commercial Officer | ▼ SELL10b5-1 | $12K | |
| Sep 10 | Mark HopmanChief Commercial Officer | ▼ SELL10b5-1 | $681K | |
| Sep 4 | Sean SaintCEO | ▼ SELL10b5-1 | $113K | |
| Sep 3 | Sean SaintCEO | ▼ SELL | $322K | |
| Sep 3 | Stephen FeiderCFO | ▼ SELL | $128K | |
| Sep 3 | Mark HopmanChief Commercial Officer | ▼ SELL | $102K | |
| Sep 3 | Mike MensingerChief Product Officer | ▼ SELL | $84K | |
| Sep 3 | Steven Jon RussellChief Medical Officer | ▼ SELL | $81K | |
| Jun 30 | Stephen FeiderCFO | ▼ SELL10b5-1 | $87K | |
| Jun 30 | Stephen FeiderCFO | ▼ SELL10b5-1 | $83K | |
| Jun 25 | Christy JonesDirector | ▼ SELL10b5-1 | $21K | |
| Jun 25 | Mark HopmanChief Commercial Officer | ▼ SELL10b5-1 | $19K |